The morally ground-shifting legacy of Ian Wilmut and Dolly the sheep
By Gregory E. Kaebnick,
STAT
| 09. 15. 2023
Ian Wilmut, the British scientist behind the first-ever cloning of a mammal, died Sept. 10, leaving behind a twofold legacy. One part is groundbreaking science. Creating Dolly required a combination of genome manipulation and reproductive tools that helped launch what is sometimes called “reprogenetics,” a basket of reproductive and genetic technologies that allow for greater control over human procreation and generated work that ranges from human-animal chimeras to the “de-extinction” of mammoths. By demonstrating that differentiated adult cells could be forced by the right chemical signals to become pluripotent stem cells, Wilmut’s work also provided the basis for Shinya Yamanaka’s Nobel Prize-winning work.
Besides being groundbreaking science, Dolly was morally ground-shifting. Perhaps more than any other biotech advance, Dolly symbolized growing human power over nature. But the Dolly project was deeply troubling to most observers. Kept a close secret by the Roslin Institute and initially disclosed in a media leak in 1997, about eight months after her birth, Dolly caught everyone by surprise. At the same time, genetically modified crops were being rolled out quickly and...
Related Articles
By Maggie Astor, The New York Times | 06.23.2026
Every year, patients undergo millions of in vitro fertilization procedures worldwide. Only a minority result in a live birth.
In an effort to improve the odds, scientists have developed an array of “add-ons” that could in theory identify the most...
By Carl Zimmer and Catrin Einhorn, The New York Times | 06.25.2026
The Trump administration and a company that is promising to bring long-gone animals back from extinction announced a partnership on Thursday to preserve cells, tissue and DNA from threatened and endangered species.
The company, Colossal Biosciences, said its goal was...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Philip Ball , Nature | 06.17.2026
Our genomes are full of mutations that have the potential to damage our health or even kill us. Yet most of them rarely cause problems. Why? It’s partly thanks to a family of proteins that mask, or ‘buffer’, the ill...